Drug intelligence / Profile preview

ATX-401

Development stage: Discontinued
Lead developer: Aurobac Therapeutics
Modality: Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Parenteral, Intravenous (iv)

Overview

ATX-401 is an engineered Gram-negative lysin (endolysin) developed as a recombinant protein antibacterial agent. Its mechanism of action involves cell wall inhibition by targeting and degrading the peptidoglycan layer of Gram-negative bacteria. Originally developed by ContraFect and later by Aurobac Therapeutics, it was intended for the treatment of serious Gram-negative infections. The drug represents a novel approach to combating antibiotic-resistant bacterial pathogens through enzymatic lysis rather than traditional small molecule antibiotics[1][3].

Other names: ATX 401ATX401ATX-401CF 370CF370CF-370GN 370GN370GN-370

Targets

PG (Prostaglandin)

Beyond the preview

Go deeper on ATX-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATX-401.

Explore the full profile